Literature DB >> 15388472

Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.

Lois M Ednie1, Glenn Pankuch, Peter C Appelbaum.   

Abstract

The MICs of LBM415, a new peptide diformylase inhibitor, were evaluated and ranged from 0.03 to 4.0 microg/ml for 300 pneumococci, irrespective of their beta-lactam, macrolide, and quinolone susceptibilities. By comparison, vancomycin, teicoplanin, linezolid, and quinupristin-dalfopristin were also active, with MICs </=2.0 microg/ml. Gatifloxacin and moxifloxacin were the most active quinolones tested, while the MICs of the beta-lactams rose with those of penicillin G. LBM415 at two times the MIC was bactericidal (99.9% killing) against six strains after 24 h.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15388472      PMCID： PMC521909          DOI： 10.1128/AAC.48.10.4027-4032.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  J Liñares; A G de la Campa; R Pallares
Journal:  N Engl J Med       Date:  1999-11-11       Impact factor: 91.245

Review 2.  Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?

Authors:  D M Livermore
Journal:  J Antimicrob Chemother       Date:  2000-09       Impact factor: 5.790

3.  Quality control guidelines for MIC susceptibility testing of NVP PDF-713: a novel peptide deformylase inhibitor.

Authors:  Tamara R Anderegg; Douglas J Biedenbach; Ronald N Jones
Journal:  Int J Antimicrob Agents       Date:  2003-07       Impact factor: 5.283

4.  In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.

Authors:  E Cercenado; F García-Garrote; E Bouza
Journal:  J Antimicrob Chemother       Date:  2001-01       Impact factor: 5.790

5.  Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.

Authors:  C J Henwood; D M Livermore; A P Johnson; D James; M Warner; A Gardiner
Journal:  J Antimicrob Chemother       Date:  2000-12       Impact factor: 5.790

6.  Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.

Authors:  M R Jacobs; S Bajaksouzian; A Zilles; G Lin; G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

7.  Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.

Authors:  D L Stevens; L G Smith; J B Bruss; M A McConnell-Martin; S E Duvall; W M Todd; B Hafkin
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

8.  Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents.

Authors:  Dianne B Hoellman; Gengrong Lin; Lois M Ednie; Ashok Rattan; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

9.  Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor.

Authors:  Ronald N Jones; Paul R Rhomberg
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

10.  Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials.

Authors:  Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Journal:  J Antimicrob Chemother       Date:  2003-02       Impact factor: 5.790
View more
  10 in total

1.  Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.

Authors:  Klaudia Kosowska-Shick; Kim L Credito; Glenn A Pankuch; Bonifacio DeWasse; Pamela McGhee; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Activity of LBM415 compared to those of 11 other agents against Haemophilus species.

Authors:  Tatiana Bogdanovich; Kathy A Smith; Catherine Clark; Glenn A Pankuch; Gengrong Lin; Pamela McGhee; Bonifacio Dewasse; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  Monica Fonseca-Aten; Christine M Salvatore; Asunción Mejías; Ana M Ríos; Susana Chávez-Bueno; Kathy Katz; Ana M Gómez; George H McCracken; R Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

4.  Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.

Authors:  Thomas R Fritsche; Helio S Sader; Roy Cleeland; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 5.  Advances in MRSA drug discovery: where are we and where do we need to be?

Authors:  Michio Kurosu; Shajila Siricilla; Katsuhiko Mitachi
Journal:  Expert Opin Drug Discov       Date:  2013-07-06       Impact factor: 6.098

6.  In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.

Authors:  Colin S Osborne; Georg Neckermann; Evelin Fischer; Robert Pecanka; Donghui Yu; Kari Manni; Julie Goldovitz; Kerri Amaral; JoAnn Dzink-Fox; Neil S Ryder
Journal:  Antimicrob Agents Chemother       Date:  2009-07-13       Impact factor: 5.191

Review 7.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.

Authors:  Ruth E Caughlan; Shubha Sriram; Denis M Daigle; Angela L Woods; Jennifer Buco; Ron L Peterson; Joann Dzink-Fox; Susan Walker; Charles R Dean
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

9.  Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322.

Authors:  Karen O'Dwyer; Meredith Hackel; Sarah Hightower; Daryl Hoban; Samuel Bouchillon; Donghui Qin; Kelly Aubart; Magdalena Zalacain; Deborah Butler
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

10.  Drug forecast - the peptide deformylase inhibitors as antibacterial agents.

Authors:  David R P Guay
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.